surmount-1 trial tirzepatide obesity without diabetes (ZEPBOUND) Approved for Chronic Weight Management in Adults with ✨ The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 kg/ m2 or New GLP-1 clinical trial data

This spacing strategy works best for once-weekly tirzepatide injections, which remain active throughout the week

Its primary purpose is letting your body adjust to the medication

In clinical trials of Zepbound, around 7% of people taking 15 mg of the drug, 6% of those taking 10 mg, and 5% of those taking 5 mg experienced fatigue, compared with only 3% of those taking a placebo

These properties have led to the development of GLP-1 receptor agonists (RAs) and, more recently, a dual GIP/GLP-1 RA for the management of type 2 diabetes and for weight management with or without diabetes

They represent a tool that, combined with lifestyle modifications, may help some people achieve meaningful weight loss

Make sure a clinician reviews your request Your health is taken very seriously, which is why our UK-approved prescribers review every message and request that you submit